Wilson Sonsini Goodrich & Rosati advised OneStream on the offering, Jones Day advised Kohlberg Kravis Roberts & Co. L.P. (“KKR”) and Latham & Watkins advised the...
You must be a Standard 1 Year member to access this content.
Cravath, Swaine & Moore represented Illumina, Inc. on the transaction, and Latham & Watkins represented GRAIL, LLC. GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises e.l.f. Beauty in its acquisition of Naturium. e.l.f. Beauty (NYSE: ELF) has announced it has signed a definitive agreement to acquire Naturium,...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell and Paul Hastings LLP are advising Francisco Partners and TPG, and Latham & Watkins LLP is advising New Relic on the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
You must be a Standard 1 Year member to access this content.
Cooley advised Reneo, and Latham & Watkins advised the underwriters and placement agents. Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented UNITY Biotechnology in the transaction. UNITY Biotechnology, Inc. (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented AMD, while Davis Polk advised the representatives of the several underwriters in the offering. AMD (NASDAQ: AMD) has priced an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Silver Spike Acquisition Corp. II on the deal, while Latham & Watkins represented Eleusis. Silver Spike Acquisition Corp. II announced its approximately $446...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the transaction. Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...
You must be a Standard 1 Year member to access this content.
